JEW JEANNE Y 4
4 · ONYX PHARMACEUTICALS INC · Filed Dec 3, 2003
Insider Transaction Report
Form 4
JEW JEANNE Y
VP, Corporate & Commercial Dev
Transactions
- Sale
Common Stock
2003-12-02$29.70/sh−1,400$41,580→ 9,700 total - Sale
Common Stock
2003-12-02$29.50/sh−200$5,901→ 8,600 total - Sale
Common Stock
2003-12-02$29.80/sh−400$11,920→ 14,600 total - Sale
Common Stock
2003-12-02$29.74/sh−700$20,818→ 11,700 total - Sale
Common Stock
2003-12-02$29.42/sh−5,825$171,372→ 400 total - Exercise/Conversion
Stock Option (Right to Buy)
2003-12-02−15,000→ 85,000 totalExercise: $6.46From: 2003-11-25Exp: 2013-11-25→ Common Stock (15,000 underlying) - Exercise/Conversion
Common Stock
2003-12-02$6.46/sh+15,000$96,900→ 15,000 total - Sale
Common Stock
2003-12-02$29.72/sh−500$14,860→ 11,100 total - Sale
Common Stock
2003-12-02$29.55/sh−600$17,730→ 8,800 total - Sale
Common Stock
2003-12-02$29.79/sh−1,500$44,685→ 13,100 total - Sale
Common Stock
2003-12-02$29.50/sh−675$19,913→ 6,725 total - Sale
Common Stock
2003-12-02$29.78/sh−300$8,934→ 12,800 total - Sale
Common Stock
2003-12-02$29.76/sh−100$2,976→ 12,400 total
Footnotes (1)
- [F1]The option becomes exercisable as to 25% on the first anniversary of the date of grant and 1/48th monthly thereafter.